A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 07 Oct 2019 Status changed from active, no longer recruiting to completed.
- 10 Jun 2019 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 10 Jun 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.